EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #05445
用于人间充质干细胞的无动物成分培养基
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。
总览
使用MesenCult™-ACF Plus培养基实现人间充质基质细胞（MSCs）的一致、无血清扩增。该培养基不含动物成分（ACF) 和细胞外囊泡（EV），可支持来自多种组织来源（包括骨髓和脂肪组织）的MSC的高效增殖，同时保留MSC表型和三谱系分化潜能。
与含血清或去除EV的培养基相比，MesenCult™-ACF Plus提供高效的MSC扩增，并消除了血清来源成分和外源EV带来的变异性。干净、无EV的背景还支持下游EV研究，无需切换培养基。有关使用该系统生成EV的指导说明，请参阅我们详细的EV生成方案，并与EasySep™人细胞外囊泡正选试剂盒配合使用，以实现高效和标准化的EV回收。
MesenCult™-ACF Plus培养基试剂盒专为生成、扩增和冻存MSC以及将人多能干细胞分化为间充质祖细胞而设计，并经过优化，可实现高效一致的MSC培养。
对于无动物成分和优化的冻存，推荐使用MesenCult™-ACF冻存液来处理之前在MesenCult™培养基（包括MesenCult™-ACF Plus）中培养的人MSC。有关相关产品的完整列表（包括可用的分化培养基），请访问我们的MSC研究领域页面或通过info.cn@stemcell.com联系我们。
注意：MesenCult™-ACF Plus完全培养基必须添加L-谷氨酰胺。此外，它还需与不含动物成分的细胞附着基质配合使用，该基质作为MesenCult™-ACF Plus培养试剂盒的一部分提供。
CollPlant是细胞贴附基质中重组人胶原蛋白（rhCollagen）成分的制造商。
分类
专用培养基
细胞类型
间充质细胞，PSC衍生，间充质干/祖细胞
种属
人
应用
细胞培养，扩增，培养
品牌
MesenCult
研究领域
药物发现和毒性检测，细胞外囊泡研究，干细胞生物学
制剂类别
不含动物成分，无血清
实验数据
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (12)
文献 (15)
Optimizing mesenchymal stem cell therapy: from isolation to GMP-compliant expansion for clinical application
BMC Molecular and Cell Biology 2025 May
Abstract
Mesenchymal stem cells (MSCs) are promising for cell-based therapies targeting a wide range of diseases. However, challenges in translating MSC-based therapies to clinical applications necessitate standardized protocols following Good Manufacturing Practices (GMP) guidelines. This study aimed at developing GMP-complained protocols for FPMSCs isolation and manipulation, necessary for translational research, by (1) optimize culture of MSCs derived from an infrapatellar fat pad (FPMSC) condition through animal-free media comparison and (2) establish feasibility of MSC isolation, manufacturing and storage under GMP-compliance (GMP-FPMSC). FPMSCs from three different patients were isolated following established protocols and the efficacy of two animal component-free media formulations in the culturing media were evaluated. The impact of different media formulations on cell proliferation, purity, and potency of MSCs was evaluated through doubling time, colony forming unit assay, and percentage of MSCs, respectively. Furthermore, the isolation and expansion of GMP-FPMSCs from four additional donors were optimized and characterized at each stage according to GMP requirements. Viability and sterility were checked using Trypan Blue and Bact/Alert, respectively, while purity and identity were confirmed using Endotoxin, Mycoplasma assays, and Flow Cytometry. The study also included stability assessments post-thaw and viability assessment to determine the shelf-life of the final GMP-FPMSC product. Statistical analyses were conducted using one-way ANOVA with Tukey’s Multiple Comparisons. The study demonstrated that FPMSCs exhibited enhanced proliferation rates when cultured in MSC-Brew GMP Medium compared to standard MSC media. Cells cultured in this media showed lower doubling times across passages, indicating increased proliferation. Additionally, higher colony formation in FPMSCs cultured in MSC-Brew GMP Medium were observed, supporting enhanced potency. Data from our GMP validation, including cells from 4 different donors, showed post-thaw GMP-FPMSC maintained stem cell marker expression and all the specifications required for product release, including > 95% viability (> 70% is required) and sterility, even after extended storage (up to 180 days), demonstrating the reproducibility and potential of GMP-FPMSCs for clinical use as well as the robustness of the isolation and storage protocols. The study underscores the feasibility of FPMSCs for clinical uses under GMP conditions and emphasizes the importance of optimized culture protocols to improve cell proliferation and potency in MSC-based therapies. The online version contains supplementary material available at 10.1186/s12860-025-00539-7.
A microfluidic bone marrow chip for the safety profiling of biologics in pre-clinical drug development
Communications Biology 2025 May
Abstract
Hematologic adverse events are common dose-limiting toxicities in drug development. Classical animal models for preclinical safety assessment of immunotherapies are often limited due to insufficient cross-reactivity with non-human homologous proteins, immune system differences, and ethical considerations. Therefore, we evaluate a human bone marrow (BM) microphysiological system (MPS) for its ability to predict expected hematopoietic liabilities of immunotherapeutics. The BM-MPS consists of a closed microfluidic circuit containing a ceramic scaffold covered with human mesenchymal stromal cells and populated with human BM-derived CD34+ cells in chemically defined growth factor-enriched media. The model supports on-chip differentiation of erythroid, myeloid and NK cells from CD34+ cells over 31 days. The hematopoietic lineage balance and output is responsive to pro-inflammatory factors and cytokines. Treatment with a transferrin receptor-targeting IgG1 antibody results in inhibition of on-chip erythropoiesis. The immunocompetence of the chip is established by the addition of peripheral blood T cells in a fully autologous setup. Treatment with T cell bispecific antibodies induces T cell activation and target cell killing consistent with expected on-target off-tumor toxicities. In conclusion, this study provides a proof-of-concept that this BM-MPS is applicable for in vitro hematopoietic safety profiling of immunotherapeutics. Subject terms: Biologics, Haematopoiesis, Lab-on-a-chip, Drug safety
Autologous iPSC- and MSC-derived chondrocyte implants for cartilage repair in a miniature pig model
Stem Cell Research & Therapy 2025 Feb
Abstract
Induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (iMSCs) have greater potential for generating chondrocytes without hypertrophic and fibrotic phenotypes compared to bone marrow-derived mesenchymal stem/stromal cells (BMSCs). However, there is a lack of research demonstrating the use of autologous iMSCs for repairing articular chondral lesions in large animal models. In this study, we aimed to evaluate the effectiveness of autologous miniature pig (minipig) iMSC-chondrocyte (iMSC-Ch)-laden implants in comparison to autologous BMSC-chondrocyte (BMSC-Ch)-laden implants for cartilage repair in porcine femoral condyles. iMSCs and BMSCs were seeded into fibrin glue/nanofiber constructs and cultured with chondrogenic induction media for 7 days before implantation. To assess the regenerative capacity of the cells, 19 skeletally mature Yucatan minipigs were randomly divided into microfracture control, acellular scaffold, iMSC, and BMSC subgroups. A cylindrical defect measuring 7 mm in diameter and 0.6 mm in depth was created on the articular cartilage surface without violating the subchondral bone. The defects were then left untreated or treated with acellular or cellular implants. Both cellular implant-treated groups exhibited enhanced joint repair compared to the microfracture and acellular control groups. Immunofluorescence analysis yielded significant findings, showing that cartilage treated with iMSC-Ch implants exhibited higher expression of COL2A1 and minimal to no expression of COL1A1 and COL10A1, in contrast to the BMSC-Ch-treated group. This indicates that the iMSC-Ch implants generated more hyaline cartilage-like tissue compared to the BMSC-Ch implants. Our findings contribute to filling the knowledge gap regarding the use of autologous iPSC derivatives for cartilage repair in a translational animal model. Moreover, these results highlight their potential as a safe and effective therapeutic strategy. The online version contains supplementary material available at 10.1186/s13287-025-04215-7.
更多信息
| 物种 | 人类 |
|---|---|
| 配方 | 不含动物成分, 无血清 |
相关产品
-
STEMdiff™ 间充质祖细胞试剂盒用于分化和扩增间充质祖细胞的成分明确的培养试剂盒
-
MesenCult™ 脂肪分化试剂盒 (人)人MSCs向脂肪细胞分化的培养基
-
MesenCult™-ACF软骨细胞分化试剂盒用于MSCs向软骨细胞分化的无动物成分培养基
-
细胞外囊泡SEC柱用于从生物液体中分离细胞外囊泡的分子排阻色谱柱
-
EasySep™人总细胞外囊泡正选试剂盒<p>对来源于血浆、血清、细胞培养上清及尿液样本的细胞外囊泡（EVs）进行免疫磁珠正选分离</p>
沪公网安备31010102008431号
在线联系